1. Introduction {#sec1-molecules-22-00659}
===============

Diabetes mellitus is a group of metabolic disorders of carbohydrate metabolism characterized by high blood glucose levels (hyperglycemia), resulting from defects in insulin secretion, insulin action, or both \[[@B1-molecules-22-00659]\]. Currently, there are an estimated 422 million people have diabetes mellitus in the world, according to the latest 2016 data from the World Health Organization (WHO) \[[@B2-molecules-22-00659]\]. In diabetic patients, untreated and chronic hyperglycemia can cause serious complications, such as heart disease, stroke, blindness, high blood pressure, kidney disease, and nervous system disease \[[@B3-molecules-22-00659]\]. α-Glucosidase is a membrane-bound enzyme at the epithelium of the small intestine and hydrolyzes terminal non-reducing 1--4 linked α-glucose residues to release monomeric glucose molecules which is mainly responsible to cause hyperglycemia \[[@B4-molecules-22-00659]\]. Inhibition of α-glucosidase activity can delay carbohydrate absorption and have been used as one of the therapeutic approaches for the treatment of diabetes \[[@B4-molecules-22-00659],[@B5-molecules-22-00659]\]. Some α-glucosidase inhibitors (acarbose, miglitol, and voglibose) have been approved for clinical use and also used as anticancer \[[@B6-molecules-22-00659]\], anti-HIV \[[@B7-molecules-22-00659]\], and anti-hepatitis agents \[[@B8-molecules-22-00659]\]. Therefore, design and synthesis of small molecules as α-glucosidase inhibitors is an important research area in medicinal chemistry.

Isatin (1*H*-indole-2,3-dione, **I**) is the reference compound of an important class of nitrogen-containing aromatic heterocyclic compounds, which have been found in many plants and human blood and tissue \[[@B9-molecules-22-00659]\]. Isatin has emerged as a promising nucleus and attracted increasing attention in medicinal chemistry and drug discovery over the past decade \[[@B10-molecules-22-00659]\]. Previous literature reports indicated that isatin and its derivatives have diverse types of biological activity, including anticancer \[[@B11-molecules-22-00659]\], antibacterial \[[@B12-molecules-22-00659]\], antiviral \[[@B13-molecules-22-00659]\], anticonvulsant \[[@B14-molecules-22-00659]\], anti-inflammatory \[[@B15-molecules-22-00659]\], and antifungal activity \[[@B16-molecules-22-00659]\]. Notably, some isatin derivatives have been approved for clinic use such as sunitinib, toceranib, and nintedanib. Furthermore, Rahim et al. reported the synthesis of isatin based Schiff bases **II** ([Figure 1](#molecules-22-00659-f001){ref-type="fig"}) which showed excellent inhibitory potential many fold better than the standard acarbose \[[@B17-molecules-22-00659]\]. Sun et al. reported the synthesis of tetracyclic oxindole derivatives **III** ([Figure 1](#molecules-22-00659-f001){ref-type="fig"}) and the most active compound (IC~50~ = 0.7 μm) was about 170 times as active as acarbose \[[@B18-molecules-22-00659]\]. Recently, we have also synthesized a series of coumarin-isatin derivatives **IV** ([Figure 1](#molecules-22-00659-f001){ref-type="fig"}), and some of the obtained compound exhibited excellent α-glucosidase inhibition activity \[[@B19-molecules-22-00659]\].

On the other hand, thiazole derivatives are considered as another important class of heterocyclic compounds, which displayed a wide range of pharmacological activities such as anti-inflammatory \[[@B20-molecules-22-00659]\], anticancer \[[@B21-molecules-22-00659]\], anticonvulsant \[[@B22-molecules-22-00659]\], and antibacterial \[[@B23-molecules-22-00659]\]. It is interesting that numerous studies pointed out thiazole could be used as a useful moiety in the design of potent α-glucosidase inhibitors \[[@B24-molecules-22-00659],[@B25-molecules-22-00659],[@B26-molecules-22-00659],[@B27-molecules-22-00659],[@B28-molecules-22-00659]\]. For example, compound series **V** \[[@B25-molecules-22-00659]\], **VI** \[[@B28-molecules-22-00659]\], and **VII** \[[@B26-molecules-22-00659]\] displayed potent α-glucosidase inhibitory activity ([Figure 1](#molecules-22-00659-f001){ref-type="fig"}).

Over the years, molecular hybrid-based approaches had been exploited by researchers to discover some promising chemical architectures which containing two or more bioactive pharmacophores \[[@B29-molecules-22-00659],[@B30-molecules-22-00659]\]. Using this approach, and as part of our ongoing effort to develop potent α-glucosidase inhibitors \[[@B31-molecules-22-00659],[@B32-molecules-22-00659],[@B33-molecules-22-00659],[@B34-molecules-22-00659],[@B35-molecules-22-00659]\], herein we report the design and synthesis of a series of novel isatin-thiazole derivatives containing isatin and thiazole moieties. The synthesized compounds were evaluated for their inhibitory activity against α-glucosidase. Furthermore, molecular docking was also performed to investigate the interaction of inhibitors with enzymes.

2. Results and Discussion {#sec2-molecules-22-00659}
=========================

2.1. Chemistry {#sec2dot1-molecules-22-00659}
--------------

The synthesis of isatin-thiazole derivatives **6a**--**6p** was shown in [Scheme 1](#molecules-22-00659-sch001){ref-type="scheme"}. Reaction of commercially available isatins **1** with various alkyl halides in the presence of K~2~CO~3~ in DMF provided *N*-alkyl isatins **2**. Isatins (**1** and **2**) were stirred with thiosemicarbazide in ethanol at 45 °C for 3 h to provide the isatin thiosemicarbazones **3**. Various substitutions of acetophenone **4** were treated with NBS in the presence of *p*-toluenesulfonic acid in acetonitrile to give α-bromoacetophenone **5**. α-bromoacetophenone **5**, with appropriate isatin thiosemicarbazones **3**, was condensed in refluxing ethanol for 2 h to afford the corresponding isatin-thiazole derivatives **6a**--**6p** in moderate to high yield (52.4--78.4%). All of the title compounds **6a**--**6p** have not yet been reported in the literature.

The structures of all of the title compounds **6a**--**6p** were characterized by ^1^H-NMR spectra. The ^1^H-NMR spectrum of **6a** exhibited two singlet signals at 11.36 and 13.33 ppm, attributed to the protons of NH-indolin-2-one and =NNH group, respectively. Two doublet signals at 6.97 ppm (*J* = 8.4 Hz) and 7.52 ppm (*J* = 2.0 Hz) were attributed to C7-H and C4-H of isatin ring, respectively. The double-double peak of C6-H of the isatin ring was observed at 7.36 ppm with a coupling constant of 8.4 Hz and 2.0 Hz. Two double peaks at 7.61 and 7.85 ppm with coupling constant of 8.4 Hz were attributed to the aromatic protons of C3,5-H and C2,6-H, respectively. The hydrogen atom of thiazole ring appeared as a singlet signal at 7.74 ppm. The ^1^H-NMR spectrum of all new compounds consistent with their structures. Moreover, in their ^13^C-NMR spectra, the number of signals equals the number of different carbons in the molecule ([Supplementary Materials](#app1-molecules-22-00659){ref-type="app"}).

2.2. α-Glucosidase Inhibition Assay {#sec2dot2-molecules-22-00659}
-----------------------------------

All the synthetic compounds **6a**--**6p** were screened for their in vitro α-glucosidase inhibitory activity ([Table 1](#molecules-22-00659-t001){ref-type="table"}). The results were shown that all the tested compounds displayed potent to moderate α-glucosidase inhibitory activity with IC~50~ ranging from 5.36 ± 0.13 to 35.76 ± 0.31 μm more potent than the standard drug acarbose (IC~50~ = 817.38 ± 6.27 μm \[[@B17-molecules-22-00659],[@B36-molecules-22-00659]\]). Among the series, compounds **6a**, **6g**, **6h**, **6i**, **6j**, **6l**, **6m**, **6n**, and **6p** displayed potent inhibitory activity with IC~50~ values of 6.87 ± 0.14, 5.98 ± 0.12, 6.12 ± 0.15, 7.51 ± 0.17, 6.51 ± 0.13, 8.33 ± 0.18, 7.17 ± 0.15, 6.36 ± 0.12, and 5.36 ± 0.13 μm. In particular, compound **6p** (IC~50~ = 5.36 ± 0.13 μm) with a hydroxyl group at the 4-position of the right phenyl ring and methyl and 2-fluorobenzyl groups at 5- and N1-positions of the isatin ring, was found to be the most active compound. In comparison to compound **6p**, a decrease in activity was observed for **6i** (IC~50~ = 7.51 ± 0.17) in which 2-fluorobenzyl groups is replaced with hydrogen at N1-positions of the isatin ring. Compounds **6c**, **6k**, and **6o** also displayed good inhibition with IC~50~ value 10.34 ± 0.17, 15.68 ± 0.24, and 11.78 ± 0.21 μm, respectively. Other compounds displayed low α-glucosidase inhibitory activity. The binding interactions of the most active compounds with α-glucosidase were confirmed through molecular docking studies.

2.3. Homology Model {#sec2dot3-molecules-22-00659}
-------------------

The crystallographic structure of *Saccharomyces cerevisiae* α-glucosidase enzyme has not been reported. To understand the ligand-enzyme interactions, the 3D structure of α-glucosidase was built by means of modeller 9.15 homology modeling software (<http://salilab.org/modeller/>). The sequence in FASTA format of α-glucosidase was retrieved from UniProt (access code P53341). The crystallographic structure of *Saccharomyces cerevisiae* isomaltase (PDB ID: 3AJ7, Resolution 1.30 Å) with 72.4% of sequence identity with the target was selected as the template for homology modeling \[[@B37-molecules-22-00659]\]. The quality of homology model was verified by PROCHECK (<http://services.mbi.ucla.edu/PROCHECK/>). The result was shown that the model could be used to study the interactions between this class of compounds and the active site of α-glucosidase \[[@B35-molecules-22-00659]\].

2.4. Molecular Docking {#sec2dot4-molecules-22-00659}
----------------------

The theoretical binding mode between **6i** and *Saccharomyces cerevisiae* α-glucosidase was shown in [Figure 2](#molecules-22-00659-f002){ref-type="fig"}. Compound **6i** adopted a "V-shaped" conformation in the pocket of the α-glucosidase. The indolin-2-one scaffold of **6i** located at the hydrophobic pocket, surrounded by the residues Phe-157, Leu-176, Pro-240, Phe-300, and Leu-218, forming a stable hydrophobic binding. Detailed analysis showed that the indolin-2-one scaffold of **6i** formed CH-π interaction with the residue Phe-157. In addition, the 4-hydroxylphenyl group of **6i** formed CH-π interactions with the residues Phe-158 and Tyr-71, and arene-anion interactions with the residues Asp-68 and Asp-349. Also, the arene-cation interactions were observed between the 4-hydroxylphenyl group of **6i** and the residues Arg-439 and Arg-443. It was shown that the residues Thr-215 (bond length: 3.3 Å) and Asp-68 (length: 2.1 Å) formed two hydrogen bonds with **6i**, which was the main interaction between **6i** and α-glucosidase. On the other hand, molecular docking study of the standard drug acarbose with α-glucosidase was also performed ([Figure 2](#molecules-22-00659-f002){ref-type="fig"}B). The results were shown that compound **6i** (binding energy was about −9.2 kcal mol^−1^) has a similar binding affinity as compared to standard drug acarbose (binding energy was about −6.8 kcal mol^−1^).

To explain the activity order of **6i** and **6p** against α-glucosidase in the molecular level, **6p** was further docked into the binding pocket of α-glucosidase, and the theoretical binding mode between **6p** and α-glucosidase was shown in [Figure 3](#molecules-22-00659-f003){ref-type="fig"}A. The interaction between **6p** and α-glucosidase was nearly the same as the compound **6i** ([Figure 3](#molecules-22-00659-f003){ref-type="fig"}B). The main difference was that the 2-fluorophenyl group of **6p** formed extra hydrophobic interactions with the residues Phe-157, Leu-176, Pro-240, and Leu-218, and formed two extra hydrogen bonds with the residue Glu-276 (length: 2.4 Å) and Asp-68 (length: 2.4 Å), which made **6p** was more active than **6i** against α-glucosidase ([Figure 3](#molecules-22-00659-f003){ref-type="fig"}B). In addition, the estimated binding energies were −9.2 kcal mol^−1^ for **6i** and −10.1 kcal mol^−1^ for **6p**, respectively, which was consistent with the results of the in vitro α-glucosidase inhibitory activity.

To explain the activity order of **6b** and **6p** against α-glucosidase in the molecular level, **6b** was further docked into the binding pocket of α-glucosidase, and the theoretical binding mode between **6b** and α-glucosidase was shown in [Figure 4](#molecules-22-00659-f004){ref-type="fig"}A. Compound **6b** adopted a 'V-shaped' conformation in the pocket of the α-glucosidase. The 2-fluorophenylindolin-2-one group of **6b** stretched into the hydrophobic pocket that consisted of Phe-157, Leu-176, Pro-240, Phe-300, and Leu-218, forming a stable hydrophobic binding. Detailed analysis showed that the indolin-2-one scaffold of **6b** formed CH-π interaction with the residue Phe-157. In addition, the 4-methylphenyl group of **6b** formed CH-π interactions with the residues Phe-158 and Tyr-71, and arene-anion interactions with the residues Asp-68 and Asp-349, respectively. Also, the arene-cation interactions were observed between the 4-methylphenyl group of **6b** and the residues Arg-439 and Arg-443. It was shown that the residues Thr-215 (bond length: 3.2 Å) and Glu-276 (length: 2.4 Å) formed two hydrogen bonds with **6b**, which was the main interaction between **6b** and α-glucosidase. The interaction between **6p** and α-glucosidase was nearly the same as the compound **6b** ([Figure 4](#molecules-22-00659-f004){ref-type="fig"}B). The main difference was that the 4-methoxyphenyl group of **6p** formed an extra hydrogen bond with the residue Asp-68 (length: 2.4 Å), which made **6p** was more active than **6b** against α-glucosidase ([Figure 4](#molecules-22-00659-f004){ref-type="fig"}B). In addition, the estimated binding energies were −9.5 kcal mol^−1^ for **6b** and −10.1 kcal mol^−1^ for **6p**, respectively, which was consistent with the results of the in vitro α-glucosidase inhibitory activity.

3. Experimental Section {#sec3-molecules-22-00659}
=======================

3.1. General {#sec3dot1-molecules-22-00659}
------------

All starting materials and reagents were purchased from commercial suppliers. TLC was performed on 0.20 mm Silica Gel 60 F~254~ plates (Qingdao Ocean Chemical Factory, Shandong, China). ^1^H- and ^13^C-NMR spectra were recorded were recorded on a Bruker spectrometer (400 MHz) with TMS as an external reference and reported in parts per million.

3.2. General Procedures for the Synthesis of ***6a**--**6p*** {#sec3dot2-molecules-22-00659}
-------------------------------------------------------------

A mixture of **3** (1.0 mmol) and **5** (1.2 mmol) in EtOH (10 mL) was stirred at reflux for 2 h. After the completion of the reaction, the precipitates that formed were collected by filtration and washed with ethanol (3 × 10 mL) to give the desired products **6a***--***6p**. The spectroscopic and analytical data of compounds are as follows:

*(Z)-3-(2-(4-(4-Bromophenyl)thiazol-2-yl)hydrazono)-5-chloroindolin-2-one* (**6a**). Orange solid, yield 77.5%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 6.97 (d, 1H, *J* = 8.4 Hz, ArH), 7.36 (dd, 1H, *J* = 8.4 Hz, 2.0 Hz, ArH), 7.52 (d, 1H, *J* = 2.0 Hz, ArH), 7.61 (d, 2H, *J* = 8.4 Hz, ArH), 7.74 (s, 1H, CH-thiazole), 7.85 (d, 2H, *J* = 8.4 Hz, ArH), 11.36 (s, 1H, NH), 13.33 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 108.6, 113.0, 119.8, 121.5, 121.9, 127.1, 128.1, 128.2, 130.3, 131.6, 132.1, 132.2, 133.6, 140.4, 150.4, 163.4, 166.5.

*(Z)-1-(2-Fluorobenzyl)-5-methyl-3-(2-(4-(p-tolyl)thiazol-2-yl)hydrazono) indolin-2-one* (**6b**). Red solid, yield 52.5%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.33 (s, 6H, CH~3~), 5.06 (s, 2H, CH~2~), 6.93 (d, 1H, *J* = 8.4 Hz, ArH), 7.14--7.19 (m, 2H, ArH), 7.23--7.26 (m, 3H, ArH), 7.32--7.37 (m, 2H, ArH), 7.44 (s, 1H, ArH), 7.58 (s, 1H, ArH), 7.79 (d, 2H, *J* = 8.0 Hz, ArH), 13.22 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 21.0, 21.3, 37.4, 106.6, 110.3, 115.9 (d, 1C, *J* = 20.9 Hz), 119.7, 120.6, 122.9, 123.0, 125.2 (d, 1C, *J* = 3.4 Hz), 126.0, 126.1, 129.7, 129.9, 130.0, 130.1, 130.3 (d, 1C, *J* = 8.1 Hz), 131.2, 131.4, 131.8, 132.9, 137.8, 139.7, 151.7, 159.4 (d, 1C, *J* = 243.9 Hz), 161.8, 166.3; MS (ESI, *m*/*z*): 457.11 \[M + H\]^+^.

*(Z)-1-(2-Fluorobenzyl)-3-(2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazono)-5-methylindolin-2-one* (**6c**). Red solid, yield 77.2%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.32 (s, 3H, CH~3~), 3.79 (s, 3H, OCH~3~), 5.06 (s, 2H, CH~2~), 6.92 (d, 1H, *J* = 8.0 Hz, ArH), 6.98 (d, 2H, *J* = 8.0 Hz, ArH), 7.13--7.18 (m, 2H, ArH), 7.22--7.26 (m, 1H, ArH), 7.32--7.37 (m, 2H, ArH), 7.43 (s, 1H, ArH), 7.48 (s, 1H, CH-thiazole), 7.83 (d, 2H, *J* = 8.0 Hz, ArH), 13.21 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 21.0, 37.4, 55.6, 105.3, 110.3, 114.5, 114.7, 115.9 (d, 1C, *J* = 20.9 Hz), 119.7, 120.5, 122.9, 123.0, 125.2 (d, 1C, *J* = 3.5 Hz), 127.3, 127.6, 130.0, 130.1, 130.3 (d, 1C, *J* = 8.1 Hz), 131.2, 131.3, 132.8, 139.7, 151.5, 159.4 (d, 1C, *J* = 243.9 Hz), 159.6, 161.7; MS (ESI, *m*/*z*): 473.09 \[M + H\]^+^.

*(Z)-1-Methyl-3-(2-(4-(p-tolyl)thiazol-2-yl)hydrazono)indolin-2-one* (**6d**). Red solid, yield 75.4%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.33(s, 3H, ArCH~3~), 3.27 (s, 3H, NCH~3~), 7.15--7.19 (m, 2H, ArH), 7.23 (d, 2H, *J* = 8.0 Hz, ArH), 7.44 (t, 1H, *J* = 8.0 Hz, ArH), 7.57 (s, 1H, CH-thiazole), 7.57 (d, 1H, *J* = 8.0 Hz, ArH), 7.79 (d, 2H, *J* = 8.0 Hz, ArH), 13.26 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 21.3, 26.2, 106.4, 110.2, 119.5, 119.9, 123.3, 126.1, 129.7, 130.8, 131.6, 131.8, 137.8, 143.0, 151.6, 161.8, 166.3.

*(Z)-3-(2-(4-(4-Fluorophenyl)thiazol-2-yl)hydrazono)-1-methylindolin-2-one* (**6e**). Orange solid, yield 70.3%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 3.27 (s, 3H, NCH~3~), 7.15--7.18 (m, 2H, ArH), 7.26 (t, 2H, *J* = 8.8 Hz, ArH), 7.44 (t, 1H, *J* = 8.0 Hz, ArH), 7.57 (d, 1H, *J* = 8.0 Hz, ArH), 7.62 (s, 1H, CH-thiazole), 7.93 (dd, 2H, *J* = 8.8 Hz, 5.6 Hz, ArH), 13.25 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 26.2, 107.1, 110.3, 115.9 (d, 1C, *J* = 21.5 Hz), 119.5, 120.0, 123.4, 128.2 (d, 1C, *J* = 8.1 Hz), 130.9, 131.0 (d, 1C, *J* = 2.9 Hz), 131.1, 131.9, 143.1, 150.5, 161.1 (d, 1C, *J* = 243.7 Hz), 161.8, 166.6.

*(Z)-3-(2-(4-(4-Methoxyphenyl)thiazol-2-yl)hydrazono)-1-methylindolin-2-one* (**6f**). Red solid, yield 69.9%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 3.27 (s, 3H, NCH~3~), 3.80 (s, 3H, OCH~3~), 6.98 (d, 2H, *J* = 8.8 Hz, ArH), 7.15--7.19 (m, 2H, ArH), 7.44 (t, 1H, *J* = 8.0 Hz, ArH), 7.48 (s, 1H, CH-thiazole), 7.58 (d, 1H, *J* = 7.2 Hz, ArH), 7.83 (d, 2H, *J* = 8.8 Hz, ArH), 13.26 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 26.2, 55.6, 105.2, 110.3, 114.5, 114.7, 119.5, 119.9, 123.4, 127.3, 127.5, 127.6, 130.8, 131.6, 143.0, 151.5, 159.6, 161.8, 166.3.

*(Z)-3-(2-(4-(4-Chlorophenyl)thiazol-2-yl)hydrazono)indolin-2-one* (**6g**). Orange solid, yield 66.9%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 6.96 (d, 1H, *J* = 8.8 Hz, ArH), 7.10 (t, 1H, *J* = 8.8 Hz, ArH), 7.35 (t, 1H, *J* = 8.8 Hz, ArH), 7.47 (d, 2H, *J* = 8.8 Hz, ArH), 7.54 (d, 1H, *J* = 8.8 Hz, ArH), 7.70 (s, 1H, CH-thiazole), 7.92 (d, 2H, *J* = 8.8 Hz, ArH), 11.26 (s, 1H, NH-indolin-2-one),13.35 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) *δ*: 108.0, 111.5, 120.2, 120.3, 122.9, 127.9, 129.1, 131.0, 132.7, 132.9, 133.3, 141.8, 150.3, 163.6, 166.7.

*(Z)-3-(2-(4-(4-Bromophenyl)thiazol-2-yl)hydrazono)-5,7-dimethylindolin-2-one* (**6h**). Orange solid, yield 64.4%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.21 (s, 3H, ArCH~3~), 2.29 (s, 3H, ArCH~3~), 6.99 (s, 1H, ArH), 7.19 (s, 1H, ArH), 7.61 (d, 2H, *J* = 8.8 Hz, ArH), 7.71 (s, 1H, CH-thiazole), 7.85 (d, 2H, *J* = 8.8 Hz, ArH), 11.22 (s, 1H, NH-indolin-2-one), 13.40 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 16.3, 20.9, 107.9, 118.1, 119.9, 120.6, 121.4, 128.2, 131.9, 132.0, 132.9, 133.2, 133.7, 138.2, 150.3, 164.2, 166.7.

*(Z)-3-(2-(4-(4-Hydroxyphenyl)thiazol-2-yl)hydrazono)-5-methylindolin-2-one* (**6i**). Orange solid, yield 52.4%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.33 (s, 3H, ArCH~3~), 6.80 (d, 2H, *J* = 8.8 Hz, ArH), 6.85 (d, 1H, *J* = 8.0 Hz, ArH), 7.15 (d, 1H, *J* = 8.0 Hz, ArH), 7.36 (s, 2H, CH-thiazole and ArH), 7.71 (d, 2H, *J* = 8.8 Hz, ArH), 11.16 (s, 1H, NH-indolin-2-one), 13.35 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 21.0, 104.2, 111.3, 115.6, 115.9, 120.2, 120.6, 125.6, 127.6, 129.9, 131.4, 131.9, 132.7, 139.5, 151.5, 157.9, 163.7, 166.3.

*(Z)-3-(2-(4-(4-Fluorophenyl)thiazol-2-yl)hydrazono)-5,7-dimethylindolin-2-one* (**6j**). Orange solid, yield 59.6%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.21 (s, 3H, ArCH~3~), 2.29 (s, 3H, ArCH~3~), 6.99 (s, 1H, ArH), 7.19 (s, 1H, ArH), 7.26 (t, 2H, *J* = 8.8 Hz), 7.61 (s, 1H, CH-thiazole), 7.93 (d, 2H, *J* = 8.8 Hz, 5.6 Hz, ArH), 11.22 (s, 1H, NH-indolin-2-one), 13.39 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 16.3, 20.9, 106.8, 115.8 (d, 1C, *J* = 21.5 Hz), 118.1, 119.9, 120.6, 128.2 (d, 1C, *J* = 8.1 Hz), 131.1 (d, 1C, *J* = 2.7 Hz), 131.8, 132.8, 133.1, 138.2, 150.5, 161.1 (d, 1C, *J* = 243.7 Hz), 164.2, 166.6.

*(Z)-5,7-Dimethyl-3-(2-(4-(p-tolyl)thiazol-2-yl)hydrazono)indolin-2-one* (**6k**). Orange solid, yield 62.1%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.21 (s, 3H, ArCH~3~), 2.29 (s, 3H, ArCH~3~), 2.34 (s, 3H, ArCH~3~), 6.99 (s, 1H, ArH), 7.20 (s, 1H, ArH), 7.23 (d, 2H, *J* = 8.0 Hz, ArH), 7.55 (s, 1H, CH-thiazole), 7.79 (d, 2H, *J* = 8.0 Hz, ArH),11.22 (s, 1H, NH-indolin-2-one), 13.39 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 16.3, 20.9, 21.3, 106.2, 118.1, 119.9, 120.6, 126.1, 129.7, 131.9, 132.8, 133.0, 137.7, 138.2, 151.6, 164.2, 166.4.

*(Z)-5-Fluoro-3-(2-(4-(p-tolyl)thiazol-2-yl)hydrazono)indolin-2-one* (**6l**). Orange solid, yield 60.8%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.24 (s, 3H, ArCH~3~), 6.96 (dd, 1H, *J* = 8.4 Hz, 4.4 Hz, ArH), 7.19 (dt, 1H, *J* = 8.4 Hz, 2.4 Hz, ArH), 7.23 (d, 2H, *J* = 8.0 Hz, ArH), 7.35 (dd, 1H, *J* = 8.4 Hz, 2.4 Hz, ArH), 7.59 (s, 1H, CH-thiazole), 7.79 (d, 2H, *J* = 8.0 Hz, ArH), 11.28 (s, 1H, NH-indolin-2-one), 13.39 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 21.3, 106.7, 107.1, 107.4, 112.5 112.6, 117.0 (d, 1C, *J* = 24.5 Hz), 121.4 (d, 1C, *J* = 8.9 Hz), 125.9, 126.1, 129.7, 129.9, 131.7, 131.9 (d, 1C, *J* = 3.1 Hz), 137.8, 137.9, 151.7, 157.6 (d, 1C, *J* = 236.4 Hz), 163.8, 166.1.

*(Z)-5-Fluoro-3-(2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)indolin-2-one* (**6m**). Orange solid, yield 57.7%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 6.95 (dd, 1H, *J* = 8.4 Hz, 4.4 Hz, ArH), 7.19 (dt, 1H, *J* = 8.4 Hz, 2.4 Hz, ArH), 7.25 (d, 2H, *J* = 8.8 Hz, ArH), 7.35 (dd, 1H, *J* = 8.4 Hz, 2.4 Hz, ArH), 7.66 (s, 1H, CH-thiazole), 7.94 (dd, 2H, *J* = 8.8 Hz, 5.6 Hz, ArH), 11.28 (s, 1H, NH-indolin-2-one), 13.39 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 107.2, 107.4, 107.4, 112.5, 112.6, 115.9 (d, 1C, *J* = 21.4 Hz), 116.2 (d, 1C, *J* = 21.5 Hz), 117.1, 117.3, 121.4, 121.5, 128.2, 128.3, 128.4, 131.0 (d, 1C, *J* = 2.9 Hz), 132.0 (d, 1C, *J* = 3.6 Hz), 138.0, 150.5, 157.6 (d, 1C, *J* = 236.3 Hz), 161.1 (d, 1C, *J* = 243.6 Hz), 163.8, 166.3.

*(Z)-3-(2-(4-(4-Fluorophenyl)thiazol-2-yl)hydrazono)indolin-2-one* (**6n**). Orange solid, yield 78.4%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) *δ:* 6.97 (d, 1H, *J* = 8.0 Hz, ArH), 7.10 (t, 1H, *J* = 8.0 Hz, ArH), 7.26 (d, 2H, *J* = 8.8 Hz, ArH), 7.36 (t, 1H, *J* = 8.0 Hz, ArH), 7.54 (d, 1H, *J* = 8.0 Hz, ArH), 7.62 (s, 1H, CH-thiazole), 7.94 (dd, 2H, *J* = 8.8 Hz, 5.6 Hz, ArH), 11.27 (s, 1H, NH-indolin-2-one), 13.35 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 117.0, 111.5, 115.9 (d, 1C, *J* = 21.4 Hz), 120.2, 120.3, 122.9, 128.2 (d, 1C, *J* = 8.1 Hz), 130.9, 131.1 (d, 1C, *J* = 2.9 Hz), 132.6, 141.8, 150.5, 161.1(d, 1C, *J* = 243.6 Hz), 163.6, 166.6.

*(Z)-3-(2-(4-(p-Tolyl)thiazol-2-yl)hydrazono)indolin-2-one* (**6o**). Red solid, yield 73.3%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.34 (s, 3H, ArCH~3~), 6.97 (d, 1H, *J* = 8.0 Hz, ArH), 7.10 (t, 1H, *J* = 8.0 Hz, ArH), 7.23 (d, 2H, *J* = 8.0 Hz, ArH), 7.35 (t, 1H, *J* = 8.0 Hz, ArH), 7.54--7.56 (m, 2H, CH-thiazole and ArH), 7.79 (d, 2H, *J* = 8.4 Hz, ArH), 11.27 (s, 1H, NH-indolin-2-one), 13.35 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 21.3, 106.3, 111.5, 120.2, 120.3, 122.9, 126.1, 129.7, 129.8, 130.9, 131.8, 132.5, 137.8, 141.7, 151.6, 163.7, 166.4.

*(Z)-1-(2-Fluorobenzyl)-3-(2-(4-(4-hydroxyphenyl)thiazol-2-yl)hydrazono)-5-methylindolin-2-one* (**6p**). Red solid, yield 53.1%, ^1^H-NMR (*d*~6~-DMSO, 400 MHz) δ: 2.33 (s, 3H, ArCH~3~), 5.07 (s, 2H, ArCH~2~), 6.81 (d, 2H, *J* = 7.2 Hz, ArH), 6.93 (d, 1H, *J* = 7.2 Hz, ArH), 7.12--7.25 (m, 3H, ArH), 7.36--7.44 (m, 3H), 7.72 (d, 2H, *J* = 7.2 Hz, ArH), 9.62 (s, 1H, OH), 13.21 (s, 1H, NH); ^13^C-NMR (*d*~6~-DMSO, 100 MHz) δ: 21.0, 37.4, 104.4, 110.3, 115.9, 115.9 (d, 1C, *J* = 23.0 Hz), 119.8, 120.5, 122.9, 123.0, 125.2, 125.8, 127.6, 130.0, 130.2 (d, 1C, *J* = 8.1 Hz), 131.1, 132.8, 139.6, 151.9, 157.9, 159.4 (d, 1C, *J* = 237.9 Hz), 166.0; MS (ESI, *m*/*z*): 459.06 \[M + H\]^+^.

3.3. In Vitro Assay of α-Glucosidase Inhibitory Activity {#sec3dot3-molecules-22-00659}
--------------------------------------------------------

According to the literature procedure \[[@B36-molecules-22-00659]\], α-Glucosidase inhibitory activity was assayed by using 0.1 M phosphate buffer (pH 6.8) at 37 °C. The enzyme (0.1 U/mL) in phosphate buffer saline was incubated with various concentrations of test compounds at 37 °C for 15 min. Then 1.25 mM *p*-nitrophenyl α-[d]{.smallcaps}-glucopyranoside was added to the mixture as a substrate, after further incubation at 37 °C for 30 min. The absorbance was measured spectrophotometrically at 405 nm. The sample solution was replaced by DMSO as a control. Acarbose was used as a positive control. All experiments were carried out in triplicates. The % inhibition has been obtained using the formula: inhibition (%) = (1 − ∆Asample/∆Acontrol) × 100%. IC~50~ value is defined as a concentration of samples inhibiting 50% of α-glucosidase activity under the stated assay conditions.

3.4. Molecular Docking {#sec3dot4-molecules-22-00659}
----------------------

Molecular docking studies were performed to investigate the binding mode between the compounds **6b**, **6i**, **6p**, and α-glucosidase using Autodock vina 1.1.2 \[[@B38-molecules-22-00659]\]. The 3D structures of **6i** and **6p** were obtained by ChemBioDraw Ultra 14.0 and ChemBio3D Ultra 14.0 softwares. The AutoDockTools 1.5.6 package was employed to generate the docking input files \[[@B39-molecules-22-00659],[@B40-molecules-22-00659]\]. The search grid of α-glucosidase was identified as center_x: −19.676, center_y: −7.243, and center_z: −21.469 with dimensions size_x: 15, size_y: 15, and size_z: 15. The value of exhaustiveness was set to 20. For Vina docking, the default parameters were used if it was not mentioned. The best-scoring poses as judged by the Vina docking score were chosen and visually analyzed using PyMOL 1.7.6 software (Schrödinger^®^, New York, NY, USA) (<http://www.pymol.org/>).

4. Conclusions {#sec4-molecules-22-00659}
==============

In conclusion, we designed and synthesized a novel series of α-glucosidase inhibitor based on the molecular hybrid-based approaches. All the target compounds displayed potent to moderate α-glucosidase inhibitory activity with IC~50~ ranging from 5.36 ± 0.13 to 35.76 ± 0.31 μm as compared to the standard drug acarbose (IC~50~ = 817.38 ± 6.27 μm). Among the series, compound **6p** bearing a hydroxyl group at the 4-position of the right phenyl and 2-fluorobenzyl substituent at the N1-positions of the 5-methylisatin displayed the highest inhibitory activity with an IC~50~ value of 5.36 ± 0.13 μm. Furthermore, molecular docking studies revealed the existence of hydrophobic interaction, CH-π interaction, arene-anion interaction, arene-cation interaction, and hydrogen bond between these compounds and α-glucosidase enzyme.
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Figures, Scheme and Table
=========================

![The chemical structures of the reported α-glucosidase inhibitors containing isatin or thiazole moiety.](molecules-22-00659-g001){#molecules-22-00659-f001}

![*Reagents and conditions*: (**a**) R~2~X, K~2~CO~3~, DMF, room temperature, 2 h; (**b**) EtOH, 45 °C, 3 h; (**c**) *p*-MeC~6~H~4~SO~3~H, NBS, CH~3~CN, reflux, 2 h; (**d**) EtOH, reflux, 2 h.](molecules-22-00659-sch001){#molecules-22-00659-sch001}

![Compound **6i** (**A**) and acarbose (**B**) was docked to the binding pocket of the *Saccharomyces cerevisiae* α-glucosidase.](molecules-22-00659-g002){#molecules-22-00659-f002}

![(**A**) Compound **6p** was docked to the binding pocket of the *Saccharomyces cerevisiae* α-glucosidase. (**B**) Compounds **6i** and **6p** were docked to the binding pocket of the *Saccharomyces cerevisiae* α-glucosidase (overlapped).](molecules-22-00659-g003){#molecules-22-00659-f003}

![(**A**) Compound **6b** was docked to the binding pocket of the *Saccharomyces cerevisiae* α-glucosidase. (**B**) Compounds **6b** and **6p** were docked to the binding pocket of the *Saccharomyces cerevisiae* α-glucosidase (overlapped).](molecules-22-00659-g004){#molecules-22-00659-f004}

molecules-22-00659-t001_Table 1

###### 

α-Glucosidase inhibitory activity of novel isatin-thiazole derivatives (**6a**--**6p**).

  Compound       R~1~        R~2~         R~3~   IC~50~ (μm) ^a^
  -------------- ----------- ------------ ------ -----------------
  **6a**         5-Cl        H            Br     6.87 ± 0.14
  **6b**         5-Me        2-F-benzyl   Me     35.76 ± 0.31
  **6c**         5-Me        2-F-benzyl   MeO    10.34 ± 0.17
  **6d**         H           Me           Me     32.17 ± 0.29
  **6e**         H           Me           F      33.20 ± 0.24
  **6f**         H           Me           MeO    24.17 ± 0.28
  **6g**         H           H            Cl     5.98 ± 0.12
  **6h**         5.7-Me~2~   H            Br     6.12 ± 0.15
  **6i**         5-Me        H            OH     7.51 ± 0.17
  **6j**         5.7-Me~2~   H            F      6.51 ± 0.13
  **6k**         5.7-Me~2~   H            Me     15.68 ± 0.24
  **6l**         5-F         H            Me     8.33 ± 0.18
  **6m**         5-F         H            F      7.17 ± 0.15
  **6n**         H           H            F      6.36 ± 0.12
  **6o**         H           H            Me     11.78 ± 0.21
  **6p**         5-Me        2-F-benzyl   OH     5.36 ± 0.13
  **Acarbose**                                   817.38 ± 6.27

^a^ Acarbose is standard for α-glucosidase inhibition activity.
